Last Updated : December 23, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Humira | Adalimumab | ulcerative colitis | Withdrawn | |||
Humira | Adalimumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Arthritis, Psoriatic | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Ankylosing spondylitis (AS) | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Crohn's disease | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Psoriasis | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Hidradenitis suppurativa | Reimburse with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
HyQvia | immune globulin human and recombinant human hyaluronidase | Humoral immunodeficiency | Reimburse with clinical criteria and/or conditions | Complete |